Results 21 to 30 of about 57,494 (245)
Scientific Reports, 2022 PCSK9 is an effective target for lowering LDL-c. Previously, a camelid-human chimeric heavy chain antibody VHH-B11-Fc targeting human PCSK9 was designed. It had a potent hypolipidemic effect.
Xinyang Li +4 more
doaj +1 more source
Single VHH-directed BCMA CAR-NK cells for multiple myeloma
Experimental Hematology & Oncology, 2023 Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells.
Quan Ren +7 more
semanticscholar +1 more source
Structural Classification of CDR-H3 in Single-Domain VHH Antibodies.
Methods in molecular biology, 2023 The immune systems protect vertebrates from foreign molecules or antigens, and antibodies are important mediators of this system. The sequences and structural features of antibodies vary depending on species.
Daisuke Kuroda, K. Tsumoto
semanticscholar +1 more source
Seed-produced anti-globulin VHH-Fc antibodies retrieve globulin precursors in the insoluble fraction and modulate the Arabidopsis thaliana seed subcellular morphology [PDF]
, 2020 Key message Nanobody-heavy chain (VHH-Fc) antibody formats have the potential to immunomodulate even highly accumulating proteins and provide a valuable tool to experimentally modulate the subcellular distribution of seed storage proteins.
Altmann, Friedrich +7 more
core +2 more sources
Frontiers in Molecular Biosciences, 2023 Introduction: In this study, we demonstrate the feasibility of yeast surface display (YSD) and nextgeneration sequencing (NGS) in combination with artificial intelligence and machine learning methods (AI/ML) for the identification of de novo humanized ...
Paul Arras +13 more
semanticscholar +1 more source
Isolation of Novel EGFR-Specific VHH Domains [PDF]
SLAS Discovery, 2009 Epidermal growth factor receptor (EGFR) is overexpressed or mutated in a high percentage of tumors. EGFR has long been considered a promising target for cancer diagnostic and therapeutic applications. However, monoclonal antibodies and other large antibody constructs diffuse into tumors slowly, limiting their efficacy. To develop lower molecular weight
Elizabeth B, Gottlin +5 more
openaire +2 more sources
Molecular Immunology, 2023 The bispecific antibody gefurulimab (also known as ALXN1720) was developed to provide patients with a subcutaneous treatment option for chronic disorders involving activation of the terminal complement pathway.
S. Jindal +14 more
semanticscholar +1 more source
Lactobacillli expressing llama VHH fragments neutralise Lactococcusphages [PDF]
BMC Biotechnology, 2007 Abstract Background Bacteriophages infecting lactic acid bacteria (LAB) are widely acknowledged as the main cause of milk fermentation failures. In this study, we describe the surface-expression as well as the secretion of two functional llama heavy-chain antibody fragments, one binding to the major capsid protein ...
Moineau Sylvain +6 more
openaire +3 more sources
mAbs, 2023 In this study, we generated a novel library approach for high throughput de novo identification of humanized single-domain antibodies following camelid immunization. To achieve this, VHH-derived complementarity-determining regions-3 (CDR3s) obtained from
Paul Arras +9 more
semanticscholar +1 more source
Peptide Linker Affecting the Activity Retention Rate of VHH in Immunosorbents
Biomolecules, 2020 VHH-based immunosorbents are an emerging and promising tool for the removal of toxic substances from plasma. However, the small size of VHHs is a double-edged sword, bringing both benefits and drawbacks to the immunosorbent.
Da Li +5 more
doaj +1 more source